Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT06277245
PHASE3

A Phase 3 Study of LNK01001 Capsule in Subjects With Moderate to Severe Atopic Dermatitis.

Sponsor: Lynk Pharmaceuticals Co., Ltd

View on ClinicalTrials.gov

Summary

This is a randomized, double-blind study comparing LNK01001 to placebo in participants with moderately to severely atopic dermatitis who were candidates for systemic therapy (ie, patients with a history of inadequate response to topical treatments, those who were using a systemic treatment, or those for whom topical treatments are otherwise medically inadvisable). The objective of this study is to evaluate the efficacy and safety of LNK01001 in adult patients with moderate to severe AD who are candidates for systemic therapy.

Official title: A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate LNK01001 in Adults Subjects With Moderate to Severe Atopic Dermatitis.

Key Details

Gender

All

Age Range

18 Years - 75 Years

Study Type

INTERVENTIONAL

Enrollment

354

Start Date

2024-02-06

Completion Date

2025-11-30

Last Updated

2025-06-27

Healthy Volunteers

No

Interventions

DRUG

LNK01001

Capsule; Oral

DRUG

Placebo

Capsule; Oral

Locations (1)

Dermatological Hospital of Southern Medical University

Guangzhou, China